RJA
VRTX icon

Ross\Johnson & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Ross\Johnson & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$497 Hold
1
– – 0.01% 134
2026
Q1 		$447 Sell
1
-1
-50% -$466 0.01% 110
2025
Q4 		$907 Buy
2
+1
+100% +$431 0.02% 104
2025
Q3 		$392 Hold
1
– – 0.01% 121
2025
Q2 		$445 Sell
1
-4
-80% -$1.84K 0.01% 107
2025
Q1 		$2.42K Buy
+5
New +$2.33K 0.04% 149

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Ross\Johnson & Associates's VRTX Position: Q2 2026 in Review

Ross\Johnson & Associates held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 1 share worth $497. The position accounts for 0.01% of the portfolio, ranked #134.

Ross\Johnson & Associates first reported a position in VRTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.42K in Q1 2025. 1,759 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Ross\Johnson & Associates held 1 share of Vertex Pharmaceuticals worth $497 as of Q2 2026.
  • Ross\Johnson & Associates left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.01% of Ross\Johnson & Associates's portfolio in Q2 2026, its #134 holding.
  • Ross\Johnson & Associates first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Ross\Johnson & Associates's Vertex Pharmaceuticals position peaked at $2.42K in Q1 2025.
  • 1,759 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Ross\Johnson & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.